EPS for ContraFect Corporation (CFRX) Expected At $-0.10

March 16, 2018 - By Stephen Andrade

 EPS for ContraFect Corporation (CFRX) Expected At $ 0.10

Analysts expect ContraFect Corporation (NASDAQ:CFRX) to report $-0.10 EPS on March, 21.They anticipate $0.05 EPS change or 33.33 % from last quarter’s $-0.15 EPS. After having $0.04 EPS previously, ContraFect Corporation’s analysts see -350.00 % EPS growth. The stock decreased 5.53% or $0.11 during the last trading session, reaching $1.88. About 194,789 shares traded. ContraFect Corporation (NASDAQ:CFRX) has declined 42.92% since March 16, 2017 and is downtrending. It has underperformed by 59.62% the S&P500.

ContraFect Corporation (NASDAQ:CFRX) Ratings Coverage

Among 3 analysts covering ContraFect (NASDAQ:CFRX), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. ContraFect has $9 highest and $3.30 lowest target. $5.65’s average target is 200.53% above currents $1.88 stock price. ContraFect had 5 analyst reports since December 31, 2015 according to SRatingsIntel. The rating was maintained by Maxim Group on Thursday, December 31 with “Buy”. As per Friday, July 22, the company rating was downgraded by Maxim Group. Roth Capital downgraded ContraFect Corporation (NASDAQ:CFRX) on Tuesday, May 10 to “Neutral” rating. William Blair initiated ContraFect Corporation (NASDAQ:CFRX) on Wednesday, September 28 with “Outperform” rating.

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. The company has market cap of $138.47 million. The Company’s lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies for the treatment of life-threatening seasonal and pandemic varieties of human influenza. It currently has negative earnings. The firm has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.